VolitionRx Reports Significant Clinical Progress and Revenue Growth in 2026

VolitionRx (VNRX) has reported a transformative year for its Nu.Q® epigenetics platform, highlighted by strong clinical validation across sepsis, oncology, and veterinary sectors. Key achievements include peer-reviewed data showing the ability to predict mortality in sepsis patients and high sensitivity rates (>94%) for detecting early-stage lung and colorectal cancers via its Capture-Seq™ technology. The company is currently in licensing discussions with over a dozen global diagnostic firms. Financially, VolitionRx has demonstrated significant momentum, reporting year-to-date revenue of $3.0 million through September 2026, representing a 134% increase compared to the same period in 2025. The company is also focused on capital efficiency, having reduced debt by over $5 million and expanding its partnership with Fujifilm Vet Systems to include feline cancer testing.

By VolitionRx Limited · PR Newswire ·

VolitionRx Reports Significant Clinical Progress and Revenue Growth in 2026

Tickers: $FUJIY

Topics: biotechnology clinical validation debt reduction licensing agreements sepsis diagnostics

Read the full article at PR Newswire

More World news